Precise, personalized therapy
An individualized approach to drug selection
Precision therapeutics, or the use of pharmacogenomic (PGx) testing in conjunction with therapeutic drug monitoring (TDM), is a rapidly evolving field with the potential to revolutionize medication selection and monitoring for individuals who take prescription medications. From managing mood disorders to evaluating for treatment-related toxicity, incorporating PGx into clinical practice can identify genetic variation associated with adverse drug reactions.
Because research studies show a significant percentage of patients possess genetic variants that impact therapeutic response, establishing patients' genetic profiles allows physicians to select medications for patients that optimize therapeutic efficacy while avoiding harmful drug reactions.
By the numbers
of individuals carry clinically actionable variants affecting medication absorption, distribution, metabolism, and excretion1
of the variability in treatment response for major depressive disorder is due to genetic variation2
Expert-backed, patient-focused testing
Mayo Clinic Laboratories’ testing is developed and validated in partnership with the Molecular Technologies Laboratory, Clinical Mass Spectrometry Laboratory, Center for Individualized Medicine (CIM), and the Schulze Center for Novel Therapeutics at Mayo Clinic. Developed in accordance with practice guidelines established by the Clinical Pharmacogenetics Implementation Consortium (CPIC) for the use of PGx testing in clinical care, our PGx evaluations provide superior analytical and clinical quality, enabling targeted detection of more clinically actionable alleles, including variants found in populations with diverse ancestry,3 compared to other testing. In addition, our testing offers:
Therapeutic areas impacted by PGx
Increase your PGx IQ
Understanding the myriad implications PGx testing has on patient treatment outcomes is integral to harnessing the full power of this emerging field. To educate providers about current and future PGx applications, Mayo Clinic offers a one-of-a-kind, online certificate course that guides attendees through foundational pharmacogenomics concepts and advanced decision-making. Engaging lectures, expert panels, case-based presentations, and patient role-play activities educate attendees on pharmacogenomics fundamentals, test interpretation, and tips on implementing pharmacogenomics into their practice.
The right medication for the right patient at the right dose
Indications for precision therapeutics testing may include:
A range of testing options
PGx testing can help guide the selection of medications for individuals with treatment-resistant depression and those with metabolic variations that impact treatment efficacy. Test results can help maximize treatment outcomes while minimizing potential drug-related toxicity from SSRI medications. Mayo Clinic Laboratories offers several TDM and PGx evaluations, including panel testing and single gene assays, to increase understanding of an individual’s genetic makeup and personalize dosing decisions.
Single gene testing
Testing for Therapeutic Drug Monitoring
To better understand a patient’s response to treatment, we offer several assays that evaluate for drug concentrations.
DXPIN | Doxepin and Nordoxepin, Serum
TRMP | Trimipramine, Serum
CLOM | Clomipramine, Serum
CITAL | Citalopram, Serum
VENLA | Venlafaxine, Serum
PARO | Paroxetine, Serum
FLUOX | Fluoxetine, Serum
DULOX | Duloxetine, Serum
Focused Pharmacogenomics Panel
Ann Moyer, M.D., Ph.D., explains Mayo Clinic Laboratories’ new focused pharmacogenomics panel, a real-time, PCR-based testing approach that assesses 10 genes known for their drug-gene associations, to provide guidance on medication selection for patients across a variety of specialties.